AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20108194 — intervention group
Group type: COMPARATOR
Intervention: Surgeon factor
Number of subjects: 681
Study 17513655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (lidocaine and remifentanil)
Number of subjects: 156
Study 17513655 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil group
Number of subjects: 156
Study 17513655 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine group
Number of subjects: 156
Study 15581385 — intervention group
Group type: EXPERIMENTAL
Intervention: Seglor (dihydroergotamine mesilate)
Number of subjects: 363
Study 15581385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 11556052 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Practice Improvement (CPI) methodology
Number of subjects: 0
Study 9793011 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interventions
Number of subjects: 0
Study 9793011 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 7986517 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warmer (Bair Hugger)
Number of subjects: 51
Study 7986517 — intervention group
Group type: COMPARATOR
Intervention: Control group (400W heat lamp)
Number of subjects: 51
Study 3044503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopenthiazide 125 micrograms
Number of subjects: 53
Study 3044503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopenthiazide 500 micrograms
Number of subjects: 53
Study 3044503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31914963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (INPULSIS)
Number of subjects: 638
Study 31914963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (INSTAGE)
Number of subjects: 638
Study 31914963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (INPULSIS)
Number of subjects: 638
Study 31633257 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback (rtfMRI-nf) signal
Number of subjects: 27
Study 31633257 — intervention group
Group type: COMPARATOR
Intervention: Sham neurofeedback signal
Number of subjects: 27
Study 28045940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (modified virtual ward model)
Number of subjects: 840
Study 28045940 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard hospital care)
Number of subjects: 840
Study 26085303 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h of total sleep deprivation
Number of subjects: 50
Study 26085303 — intervention group
Group type: COMPARATOR
Intervention: Regular sleep‐wake cycle (Control)
Number of subjects: 50
Study 21636144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 4951
Study 21636144 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score stratification
Number of subjects: 4951
Study 21636144 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score calibration and discrimination
Number of subjects: 4951
Study 21636144 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup stratification
Number of subjects: 4951
Study 21129028 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (Group-L)
Number of subjects: 70
Study 21129028 — intervention group
Group type: COMPARATOR
Intervention: No lactulose (Group-P)
Number of subjects: 70
Study 21129028 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose therapy
Number of subjects: 70
Study 16704585 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Position group (lateral position, 20 degrees head-down tilt)
Number of subjects: 72
Study 16704585 — intervention group
Group type: COMPARATOR
Intervention: Supine group
Number of subjects: 72
Study 15641635 — intervention group
Group type: EXPERIMENTAL
Intervention: Care map intervention with individual instruction and training sessions for parents
Number of subjects: 42
Study 15641635 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular care without additional training)
Number of subjects: 42
Study 11422660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine infusion (0.3 microg kg‐1 min(‐1))
Number of subjects: 6
Study 11422660 — intervention group
Group type: COMPARATOR
Intervention: Control (NaCl infusion)
Number of subjects: 6
Study 9415651 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized version of WOMAC VA3.0
Number of subjects: 30
Study 9415651 — intervention group
Group type: COMPARATOR
Intervention: Paper version of WOMAC
Number of subjects: 30
Study 7693420 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 50 x 6 cycles (Group A, n = 207)
Number of subjects: 621
Study 7693420 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 50 x 3 cycles (Group B, n = 193)
Number of subjects: 621
Study 7693420 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 75 x 3 cycles (Group C, n = 195)
Number of subjects: 621
Study 3027884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole treatment for 5 days
Number of subjects: 24
Study 3027884 — intervention group
Group type: COMPARATOR
Intervention: Control without placebo
Number of subjects: 24
Study 3027884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole treatment
Number of subjects: 24
Study 31535332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14)
Number of subjects: 7
Study 31535332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29889698 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (1 mg) with 15 mL bupivacaine 0.5%
Number of subjects: 125
Study 29889698 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone (1 mg)
Number of subjects: 125
Study 29889698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PeriD and IVDex)
Number of subjects: 125
Study 26280313 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation with foc.us tDCS
Number of subjects: 24
Study 26280313 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 24948800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic structure of motion detectors in native space-time; amplitude change over the first ∼100 ms.
Number of subjects: 0
Study 22728230 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (plus cyclic medroxyprogesterone)
Number of subjects: 69
Study 22728230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 22728230 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 69
Study 22728230 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study 22728230 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with AN
Number of subjects: 69
Study 20099269 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD+PAS (Major Depressive Disorder plus Panic-Agoraphobic Spectrum Disorders)
Number of subjects: 97
Study 20099269 — intervention group
Group type: COMPARATOR
Intervention: MDD (Major Depressive Disorder)
Number of subjects: 97
Study 17883554 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel pack
Number of subjects: 21
Study 17883554 — intervention group
Group type: COMPARATOR
Intervention: Series 5000 pack
Number of subjects: 21
Study 16351359 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-epsilon4 gene dose
Number of subjects: 0
Study 16351359 — intervention group
Group type: COMPARATOR
Intervention: Control group (noncarriers and heterozygotes)
Number of subjects: 0
Study 16351359 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-epsilon4 homozygotes
Number of subjects: 0
Study 12542203 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise subjects (active and passive head movements, walking with augmented head movements)
Number of subjects: 0
Study 12542203 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (attention without exercise)
Number of subjects: 0
Study 9706600 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1 g/8 h)
Number of subjects: 98
Study 9706600 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g/8 h) plus Metronidazole (0.5 g/8 h)
Number of subjects: 98
Study 8521151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg)
Number of subjects: 12
Study 8521151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2677125 — intervention group
Group type: EXPERIMENTAL
Intervention: lofepramine (70 mg, 105 mg, 140 mg)
Number of subjects: 6
Study 2677125 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline (50 mg)
Number of subjects: 6
Study 699626 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg diflunisal twice daily
Number of subjects: 22
Study 699626 — intervention group
Group type: COMPARATOR
Intervention: 750 mg aspirin 4-times daily
Number of subjects: 22
Study 699626 — intervention group
Group type: COMPARATOR
Intervention: 600 mg aspirin 4-times daily
Number of subjects: 22
Study 30705241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysarthria therapy via Skype (3 sessions of 40 min per week for 6 weeks)
Number of subjects: 22
Study 30705241 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (usual speech therapy from local therapist for 6 weeks)
Number of subjects: 22
Study 30705241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysarthria therapy via Skype
Number of subjects: 22
Study 28888207 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lunge stretching
Number of subjects: 40
Study 28888207 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional stretching
Number of subjects: 40
Study 28888207 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint mobilization stretching
Number of subjects: 40
Study 28888207 — intervention group
Group type: COMPARATOR
Intervention: Passive static stretching
Number of subjects: 40
Study 28888207 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study 25516993 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supply via nasal cannula at a flow of 4 L/min
Number of subjects: 36
Study 25516993 — intervention group
Group type: COMPARATOR
Intervention: Compressed air at a flow of 4 L/min
Number of subjects: 36
Study 24196599 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual step count goal-setting
Number of subjects: 136
Study 24196599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no goal-setting)
Number of subjects: 136
Study 24196599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 136
Study 21068204 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel Snus
Number of subjects: 130
Study 21068204 — intervention group
Group type: EXPERIMENTAL
Intervention: Taboka
Number of subjects: 130
Study 21068204 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal Nicotine
Number of subjects: 130
Study 19847319 — intervention group
Group type: EXPERIMENTAL
Intervention: Undenatured type II collagen (UC‐II)
Number of subjects: 0
Study 19847319 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine and chondroitin (G+C)
Number of subjects: 0
Study 16460691 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 11
Study 16460691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16460691 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime prazosin (open label)
Number of subjects: 11
Study 15307813 — intervention group
Group type: EXPERIMENTAL
Intervention: Background music (45-minute CD at naptime and bedtime for 3 weeks)
Number of subjects: 86
Study 15307813 — intervention group
Group type: COMPARATOR
Intervention: Control group (no background music)
Number of subjects: 86
Study 11298047 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior retroperitoneoscopic approach (RPA)
Number of subjects: 55
Study 11298047 — intervention group
Group type: COMPARATOR
Intervention: Lateral retroperitoneoscopic approach (RPA)
Number of subjects: 55
Study 9422296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2.5 microg x kg(‐1)) plus thiopentone
Number of subjects: 60
Study 9422296 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete muscle relaxation (> or =65%)
Number of subjects: 60
Study 9422296 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 60
Study 9422296 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete muscle relaxation (100%)
Number of subjects: 60
Study 8351758 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose prophylaxis with ciprofloxacin (500 mg)
Number of subjects: 235
Study 8351758 — intervention group
Group type: COMPARATOR
Intervention: 3-day prophylaxis with ciprofloxacin
Number of subjects: 235
Study 3304613 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 0
Study 3304613 — intervention group
Group type: COMPARATOR
Intervention: Velban, Actinomycin‐D, bleomycin, cisplatin, and cytoxan (VAB‐6)
Number of subjects: 0
Study 30876973 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan (Atr)
Number of subjects: 0
Study 30876973 — intervention group
Group type: COMPARATOR
Intervention: High glucose (HG) treatment
Number of subjects: 0
Study 29526235 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with Rosa damascena (0.08 mL every 30 min)
Number of subjects: 110
Study 29526235 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.08 mL every 30 min)
Number of subjects: 110
Study 26503310 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour supervised exercise training, 3 days/week for 8 weeks (n=10)
Number of subjects: 19
Study 26503310 — intervention group
Group type: COMPARATOR
Intervention: Equal-time health education training, 3 days/week for 8 weeks (n=9)
Number of subjects: 19
Study 25176266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous laser irradiation of blood (ILIB) with semiconductor laser (wavelength - 0.67 microns, power output - 3-2 mW) in addition to standard treatment
Number of subjects: 53
Study 25176266 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 53
Study 25176266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous laser irradiation of blood (ILIB) with semiconductor laser
Number of subjects: 53
Study 22982824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive strengthening exercise
Number of subjects: 44
Study 22982824 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy (stretching and gait training)
Number of subjects: 44
Study 20434060 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental change (introduction of 10 new low‐energy‐density foods and provision of labels for all foods sold at lunch)
Number of subjects: 96
Study 20434060 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental change plus pricing incentives and education about low‐ED eating
Number of subjects: 96
Study 20434060 — intervention group
Group type: COMPARATOR
Intervention: Both groups (environmental change and environmental change plus pricing incentives)
Number of subjects: 96
Study 17564201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare finger
Number of subjects: 0
Study 17564201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid stylus-shaped probe
Number of subjects: 0
Study 15059282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg/day for one week, with weaning over a second week)
Number of subjects: 40
Study 15059282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearing)
Number of subjects: 40
Study 11384567 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine (2%) four times daily to one eye and vehicle to the other
Number of subjects: 30
Study 11384567 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost (0.005%) once daily to both eyes
Number of subjects: 30
Study 11384567 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of pilocarpine and latanoprost
Number of subjects: 30
Study 11384567 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost (0.005%) once daily to one eye and vehicle to the other
Number of subjects: 30
Study 9223193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesacaine-CE 3%
Number of subjects: 30
Study 9223193 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 1.33%
Number of subjects: 30
Study 7967363 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin (D)
Number of subjects: 209
Study 7967363 — intervention group
Group type: COMPARATOR
Intervention: 1.36% glucose (C)
Number of subjects: 209
Study 7967363 — intervention group
Group type: COMPARATOR
Intervention: 3.86% glucose (C)
Number of subjects: 209
Study 3606916 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid anaesthesia
Number of subjects: 93
Study 3606916 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 93
Study 30085184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (DT) with a ritonavir‐boosted PI (PI/r) plus lamivudine
Number of subjects: 1051
Study 30085184 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (TT) with PI/r plus two nucleos(t)ide reverse transcriptase inhibitors (N(t)RTIs)
Number of subjects: 1051
Study 27806977 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (625 mg/d for 6 weeks)
Number of subjects: 55
Study 27806977 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent inactive treatment)
Number of subjects: 55
Study 24865619 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management treatment
Number of subjects: 428
Study 23001240 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum iron metrics (including serum ferritin, serum iron, transferrin saturation, TIBC)
Number of subjects: 341
Study 23001240 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin, serum iron, transferrin saturation, TIBC
Number of subjects: 341
Study 23001240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary iron exposures
Number of subjects: 341
Study 20798364 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Extremity Thermal Stimulation (UE-TS) for 30 minutes per day, 3 days/week for 8 weeks
Number of subjects: 23
Study 20798364 — intervention group
Group type: COMPARATOR
Intervention: Lower Extremity Thermal Stimulation (Control)
Number of subjects: 23
Study 18447214 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6), Zusanli (ST 36), Sanyinjiao (SP 6)
Number of subjects: 60
Study 18447214 — intervention group
Group type: COMPARATOR
Intervention: Medication group treated with oral administration of Weilexin
Number of subjects: 60
Study 16621194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine (G1, G2, G3, G4, and P1A)
Number of subjects: 1946
Study 16621194 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent P1A vaccine
Number of subjects: 1946
Study 16621194 — intervention group
Group type: COMPARATOR
Intervention: Vaccine group
Number of subjects: 1946
Study 16621194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-potency pentavalent vaccine
Number of subjects: 1946
Study 12536263 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day + Pindolol 2.5 mg three times a day
Number of subjects: 12
Study 12536263 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg/day
Number of subjects: 12
Study 12536263 — intervention group
Group type: COMPARATOR
Intervention: Pindolol 2.5 mg three times a day
Number of subjects: 12
Study 12536263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11236243 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF)
Number of subjects: 34
Study 11236243 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA)
Number of subjects: 34
Study 11236243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin fragment 19 (CYFRA 21-1)
Number of subjects: 34
Study 11236243 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 34
Study 11236243 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 34
Study 11236243 — intervention group
Group type: EXPERIMENTAL
Intervention: CYFRA 21-1
Number of subjects: 34
Study 11236243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of G-CSF and CEA
Number of subjects: 34
Study 8628044 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Maintenance Organization (HMO)
Number of subjects: 0
Study 8628044 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-Service Medicaid
Number of subjects: 0
Study 1596703 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alpha-interferon (5 x 10(5) iu, twice a week)
Number of subjects: 0
Study 1596703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6439100 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 734
Study 6439100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 734
Study 6439100 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 734
Study 30507032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic-powered toothbrush
Number of subjects: 32
Study 30507032 — intervention group
Group type: COMPARATOR
Intervention: Soft-bristle manual toothbrush
Number of subjects: 32
Study 29505522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (VT < 8 mL/kg) + pressure controlled ventilation (PCV)
Number of subjects: 180
Study 29505522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (VT < 8 mL/kg) + volume-controlled ventilation (VCV)
Number of subjects: 180
Study 29505522 — intervention group
Group type: COMPARATOR
Intervention: High tidal volume (VT ≥ 8 mL/kg) + pressure controlled ventilation (PCV)
Number of subjects: 180
Study 29505522 — intervention group
Group type: COMPARATOR
Intervention: High tidal volume (VT ≥ 8 mL/kg) + volume-controlled ventilation (VCV)
Number of subjects: 180
Study 26811112 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling placement with retropubic approach
Number of subjects: 2123
Study 26811112 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous bariatric surgery
Number of subjects: 2123
Study 26811112 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hemoglobin <13 g/dL
Number of subjects: 2123
Study 26811112 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal status
Number of subjects: 2123